Medicare AdvantagePrior AuthHigh impact
Olumiant (baricitinib) (Revised)
Humana·Rheumatology, Internal Medicine·Medicare Advantage
We identified it
Jul 22, 2026
Summary
Unable to complete analysis. The policy document referenced (Olumiant/baricitinib Prior Authorization for Medicare Advantage) is provided as 'Summary Only' with no actual policy content available. The source URL points to a Humana document management system that requires direct access. Billing team cannot implement changes without the specific prior authorization requirements, affected diagnoses, step therapy criteria, or effective dates contained in the full policy document.
Action Required
IMMEDIATE: Billing team must obtain the complete policy document from Humana (reference: 090009298a586838) to determine: (1) specific diagnoses requiring prior authorization for Olumiant; (2) required documentation and medical necessity criteria; (3) effective date; (4) authorization contact information; (5) whether this supersedes any previous Olumiant coverage policy. Do not process Olumiant claims until full policy content is retrieved and reviewed. Contact Humana Provider Services or access the complete policy through your Humana provider portal. Document the policy retrieval date and effective date in your compliance file.